Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alginate in Dysplastic Barrett's Esophagus
NCT03193216Phase 2Completed
- Sponsor
- Medical University of South Carolina
- Start
- Aug 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gaviscon advance in Barrett's esophagus, sponsored by Medical University of South Carolina. Primary endpoint: Percentage of Patients With Successful Eradication at 18 months. Started Aug 2017; status: completed.
02
Drugs
gaviscon advance
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT03193216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193216.